直肠癌新辅助放疗前后CD8阳性淋巴细胞浸润变化
本研究回顾性纳入34例2019至2021年接受新辅助放疗的直肠癌患者,比较长程(LCRT)与短程(SCRT)放疗前后CD8阳性肿瘤浸润淋巴细胞(TILs)数量变化。所有患者放疗后CD8阳性TILs数量与百分比均显著增加(P<0.001),SCRT组较LCRT组相对增幅更高,但未调整分析中无统计学差异(P=0.127);调整组织病理学变量后SCRT与新辅助后CD8阳性计数比值更高独立相关(P=0.03)。
要点
- 直肠癌新辅助放疗后CD8阳性TILs数量与百分比显著增加(P<0.001)。
- SCRT组中位放疗后与放疗前CD8阳性计数比值为3.1,LCRT组为2.77(P=0.127)。
- 调整组织病理学变量后,SCRT与更高的CD8阳性计数比值独立相关(P=0.03)。
核心结论
- SCRT与LCRT均显著增加直肠癌CD8阳性TILs计数与百分比,反映放疗后免疫激活;SCRT相对增幅更高,但未调整分析无统计学差异,调整组织病理学变量后SCRT独立相关。
研究设计与样本
- 回顾性研究,纳入2019至2021年间接受新辅助放疗的直肠癌患者34例,其中LCRT 23例(67.6%),SCRT 11例(32.4%),平均年龄58.56±13.59岁。
- 对活检与手术样本行免疫组化染色计数CD8阳性TILs,评估放疗后与放疗前CD8阳性计数比值与治疗组、组织病理学因素及治疗反应的关系。
主要发现
- 所有患者放疗后CD8阳性TILs数量与百分比显著增加(P<0.001)。
- LCRT组中位放疗后与放疗前CD8阳性计数比值为2.77,SCRT组为3.1(P=0.127)。
- 调整黏液组织学、手术分级与病理分期后,SCRT与更高的放疗后与放疗前CD8阳性计数比值显著相关(P=0.03)。
临床怎么用
- 放疗可增强直肠癌CD8阳性TIL浸润,支持放疗的免疫激活效应,但SCRT与LCRT的相对增幅差异需进一步验证。
- CD8阳性TILs动态变化或可作为评估放疗免疫反应的候选标记,但尚不能用于临床决策。
局限性
- 回顾性研究、样本量小(34例),SCRT组仅11例,统计效能有限。
- 未调整分析中SCRT与LCRT的CD8阳性计数比值差异无统计学意义(P=0.127)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antitumor immunity, exerted by CD8+ cytotoxic T lymphocytes, plays a vital role in tumor control. Therefore, the present study was conducted to compare the amount of CD8+ tumor-infiltrating lymphocytes (TILs) before and after either long- (LCRT) or short-course radiotherapy (SCRT) in rectal cancer. METHODS: This study retrospectively assessed rectal cancer patients treated by neoadjuvant radiotherapy between 2019 and 2021. Biopsy and surgical samples were subjected to immunohistochemical staining to count CD8+ TILs. The association between the post-to-pre-treatment CD8+ count ratio and treatment groups, histopathological factors, and response to treatment was assessed. RESULTS: A total of 34 patients were included, with 23 (67.6 %) receiving LCRT and 11 (32.4 %) receiving SCRT. The mean age was 58.56 ± 13.59 years. The number and percentage of CD8+ TILs increased significantly after radiotherapy in all patients (P < 0.001). An increase in CD8+ TILs was observed in both groups, with LCRT showing a median post-to-pre-treatment count ratio of 2.77 and SCRT showing 3.1 (P = 0.127). A generalized linear multivariate model adjusting for mucinous histology, surgical grade, and pathological stages revealed that SCRT was associated with a significantly higher post-to-pre-treatment CD8+ count ratio compared to LCRT (P = 0.03). CONCLUSION: Our study highlights that both SCRT and LCRT significantly increase CD8+ TIL count and percentage, reflecting robust immune activation after radiotherapy in rectal cancer, with SCRT showing a higher relative increase, though not statistically significant in unadjusted analyses. After adjusting for histopathological variables, SCRT was independently associated with a greater increase in CD8+ T cells.
引用
- Salarvand S, Abyaneh R, Raee A, et al. CD8-positive lymphocyte infiltration as a marker of anti-tumor immune response in rectal cancer: pre- and post-neoadjuvant radiotherapy comparison. Clin Transl Radiat Oncol. 2025. PMID: 40741211. doi:10.1016/j.ctro.2025.101018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。